At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 370 enrolled
Drug / intervention
Apixabandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Academic and Community Cancer Research United·interventional·Posted Mar 15, 2017·Updated May 18, 2025
In Brief
A Phase 3 clinical trial evaluating Apixaban for Cerebral Vein Thrombosis and 6 related conditions. Completed, enrolled 370 participants across 32 sites.
Detailed Summary
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy. Apixaban may help in prevention by blocking some of the enzymes needed for venous thrombosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Pulmonary Embolism, Splanchnic Vein Thrombosis
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartJul 2017
Primary CompletionJun 2022
Study CompletionMay 2025
TodayJul 2026
First PostedMar 15, 2017
Enrollment StartJul 14, 2017
Primary CompletionJun 7, 2022
Study CompletionMay 9, 2025
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 9.3 years ago
Interventions
Apixabandrug
Given PO